World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

DIABETIC KETOACIDOSIS ASSOCIATED WITH SGLT2 INHIBITORS: A REVIEW

Neethu J.*, Alinta S. B. Muth, Christy Surendran, Anisha D. S. and Arya Rajan

ABSTRACT

Sodium glucose co-transporter (SGLT) 2inhibitors, called as ‘gliflozins’ are a relatively new class of oral hypoglycemic agents(OHA) approved by FDA in 2013 for use in type2 diabetes mellitus. These special class of OHAs induce glycosuria by reducing renal glucose reabsorption and thereby improve glycemic control. Apart from glucose lowering effect, other metabolic benefits are affirmated and safety concerns including 3 FDA drug safety communications issued in 2015.One of it was, Diabetic ketoacidosis,which occur in presence of low insulin levels, prolonged fasting or during stressful conditions. On May2015,USFDA declared the safety announcement that SGLT2 inhibitors such as Canagliflozin, Dapagliflozin, and Empagliflozin may cause ketoacidosis which may require emergency treatment. Investigations are continuing in this safety issue.These agents are still undergoing clinical studies concerning their safety and efficacy. This review is an effort to assess diabetic ketoacidosis as a safety concern associated with SGLT2 inhibition by going through past research studies, case reports and series.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR